Development of Nodular Lesions after Dupilumab Therapy in Erythrodermic Mycosis Fungoides with Interleukin-13 Receptor alpha2 Expression
DOI:
https://doi.org/10.2340/actadv.v102.2234Keywords:
erythroderma, mycosis fungoides, dupilumab, progression, IL-13 receptor alpha 2Abstract
Abstract is missing (Short communication)
Downloads
References
Miyagaki T, Sugaya M. Immunological milieu in mycosis fungoides and Sézary syndrome. J Dermatol 2014; 41: 11-18.
https://doi.org/10.1111/1346-8138.12305 DOI: https://doi.org/10.1111/1346-8138.12305
Sugaya M. Is blocking IL-4 receptor alpha beneficial for patients with mycosis fungoides or Sézary syndrome? J Dermatol 2021; 48: e225-226.
https://doi.org/10.1111/1346-8138.15834 DOI: https://doi.org/10.1111/1346-8138.15834
Elston DM. Dupilumab and cutaneous T-cell lymphoma. J Am Acad Dermatol 2020; 83: 33-34.
https://doi.org/10.1016/j.jaad.2020.03.051 DOI: https://doi.org/10.1016/j.jaad.2020.03.051
Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine 2015; 75: 79-88.
https://doi.org/10.1016/j.cyto.2015.05.026 DOI: https://doi.org/10.1016/j.cyto.2015.05.026
Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 2015; 125: 2798-2805.
https://doi.org/10.1182/blood-2014-07-590398 DOI: https://doi.org/10.1182/blood-2014-07-590398
Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010; 16: 577-586.
https://doi.org/10.1158/1078-0432.CCR-09-2015 DOI: https://doi.org/10.1158/1078-0432.CCR-09-2015
Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012; 131: 344-356.
https://doi.org/10.1002/ijc.26366 DOI: https://doi.org/10.1002/ijc.26366
Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. IL-13 receptor alpha2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumour Biol 2016; 37: 14701-14709.
https://doi.org/10.1007/s13277-016-5346-x DOI: https://doi.org/10.1007/s13277-016-5346-x
Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
https://doi.org/10.1038/nm1332 DOI: https://doi.org/10.1038/nm1332
Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400.
https://doi.org/10.1038/sj.onc.1204383 DOI: https://doi.org/10.1038/sj.onc.1204383
Lazaridou I, Ram-Wolff C, Bouaziz JD, Bégon E, Battistella M, Rivet J, et al. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas. Acta Derm Venereol 2020; 100: adv00271.
https://doi.org/10.2340/00015555-3576 DOI: https://doi.org/10.2340/00015555-3576
Mollanazar NK, Savage KT, Pousti BT, Jariwala N, Del Guzzo C, Haun P, et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. Cutis 2020; 106: 131-132.
https://doi.org/10.12788/cutis.0066 DOI: https://doi.org/10.12788/cutis.0066
Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2021; 35: 1331-1337.
https://doi.org/10.1111/jdv.17001 DOI: https://doi.org/10.1111/jdv.17001
Published
How to Cite
License
Copyright (c) 2022 Mina Hashimoto, Tomomitsu Miyagaki, Reo Komaki, Sora Takeuchi, Takafumi Kadono
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.